These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 17991198

  • 1. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
    Suliman ME, Lindholm B, Bárány P, Qureshi AR, Stenvinkel P.
    Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
    [Abstract] [Full Text] [Related]

  • 2. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients.
    Valli A, Carrero JJ, Qureshi AR, Garibotto G, Bárány P, Axelsson J, Lindholm B, Stenvinkel P, Anderstam B, Suliman ME.
    Clin Chim Acta; 2008 Sep; 395(1-2):106-10. PubMed ID: 18565329
    [Abstract] [Full Text] [Related]

  • 3. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus.
    Suliman ME, Stenvinkel P, Bárány P, Heimbürger O, Anderstam B, Lindholm B.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S89-95. PubMed ID: 12612961
    [Abstract] [Full Text] [Related]

  • 4. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J, Kropf S, Luley C, Dierkes J.
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [Abstract] [Full Text] [Related]

  • 5. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
    Sjöberg B, Anderstam B, Suliman M, Alvestrand A.
    Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
    Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J, FAVORIT Investigators.
    Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation.
    Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Bárány P, Heimbürger O, Vonesh EF, Lindholm B.
    Nephrol Dial Transplant; 2007 Jan; 22(1):209-17. PubMed ID: 16982634
    [Abstract] [Full Text] [Related]

  • 9. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
    Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M, Sessa A.
    Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
    [Abstract] [Full Text] [Related]

  • 10. Homocysteine, B-vitamins and CVD.
    McNulty H, Pentieva K, Hoey L, Ward M.
    Proc Nutr Soc; 2008 May; 67(2):232-7. PubMed ID: 18412997
    [Abstract] [Full Text] [Related]

  • 11. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials.
    Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, Liu XL, Jin HM.
    Br J Nutr; 2012 Aug; 108(3):400-7. PubMed ID: 22244447
    [Abstract] [Full Text] [Related]

  • 12. Hyperhomocysteinemia in end-stage renal failure.
    Kes P.
    Acta Med Croatica; 2000 Aug; 54(4-5):175-81. PubMed ID: 11379482
    [Abstract] [Full Text] [Related]

  • 13. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, Soares AE, Matni AM.
    Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials.
    Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C.
    Eur Heart J; 2009 Jan; 30(1):6-15. PubMed ID: 19029125
    [Abstract] [Full Text] [Related]

  • 18. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next?
    Kalantar-Zadeh K.
    Semin Dial; 2005 Jan; 18(5):365-9. PubMed ID: 16191172
    [Abstract] [Full Text] [Related]

  • 19. It is important to lower homocysteine in dialysis patients.
    Zoccali C, Mallamaci F, Tripepi G.
    Semin Dial; 2007 Jan; 20(6):530-3. PubMed ID: 17991199
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.